Exosome News: ExoCoBio Completes Acquisition of Benev

ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publications. 

ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products.

ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publications. 

"We are very pleased with this important acquisition which will contribute to the fast growth and business expansion of ExoCoBio,” says Mr. Byong Cho, CEO/CTO of ExoCoBio, in a news released.“BENEV is a perfect complement to our mission to bridge exosome science to clinical application to further elevate exosome technology as a mega-trend in the market."

Mr. Ethan Min, CEO of BENEV, adds, "We are truly grateful and pleased to announce ExoCoBio's acquisition of BENEV. We have been on a journey together as a strategic and financial partner for the last six years since the U.S. launch of Exosome Regenerative Complex. With this acquisition, we are confident that our expertise, standing in the industry and brand, paired with ExoCoBio's science, technology, funding and pipeline products will generate a strong synergy for our strategic growth in the global medical aesthetic market."